Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Accutar’s Chimeric Degrader OK’d for Prostate Cancer Trials in China

publication date: Aug 19, 2022

Accutar Biotechnology was approved to start China trials of its oral chimeric degrader candidate in patients with metastatic Castration Resistant Prostate Cancer. The company’s AC0176 targets androgen receptor protein. Accutar, a New Jersey-Shanghai biotech uses a hybrid AI approach for drug discovery based on the physical and chemical nature of biologic systems – computational drug design followed by wet lab validation. The IND approval is the third for Accutar this year: earlier the company was approved to start a similar trial of AC0176 in the US and a China trial of AC0682 for estrogen receptor-positive breast cancer. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital